EUCTR2006-004564-32-NL进行中（未招募）不适用
The Prostate CARE Study: Capecitabine (Xeloda®) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and phase II efficacy study. - The Prostate CARE Study
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Related to prostate cancer:
- •1.Histologically documented adenocarcinoma of the prostate.
- •2.Presence of more than one osteoblastic bone metastasis confirmed by 99mTc-labeled
- •bisphosphonates bone scan performed within 8 weeks prior to study entry.
- •3.Bone pain and/or painmedication.
- •4.Clinically progressive hormone refractory disease, as documented by one or more of the following:
- •a.Two documented consecutive increases in total PSA over a previous reference value (first increase at least one week after reference value). Increased total
- •PSA level must be at least 5 µg/L.
- •b.New lesion on bone scan (progressive measurable disease).
- •c.Increase in bidimensionally measurable disease.
- •5.Karnofsky performance status ³ 60% (Appendix III).
- •6.Life expectancy of at least 3 months.
- •7.Patients with lower urinary tract obstruction or incontinence must consent to
- •catheterization of the bladder for up to 6 hours after administration of Re-188-HEDP .
- •Related to previous or concomitant therapies:
- •8.Patients receiving anti-androgen treatment can either stop or continue their treatment.
- •Patients who stop anti-androgens must demonstrate no decrease in total PSA values on
- •at least two occasions at least 1 week apart after anti-androgen withdrawal. Flutamide
- •must be discontinued for 4 weeks, and bicalutamide, megestrol acetate, cyproterone
- •acetate, or nilutamide must be discontinued for at least 6 weeks prior to study entry.
- •Patients who continue anti-androgen treatment must go on with their treatment during
- •the whole study period.
- •9.Patients under LH-RH agonists must continue their treatment.
- •Related to the patient:
- •10.Age ³ 18 years.
- •11.Ability to understand and willingness to sign a written informed consent document.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Related to prostate cancer:
- •1.Patients with pathologic long-bone fractures (unless surgically stabilized), imminent
- •pathologic long-bone fracture (cortical erosion on radiography > 50%), or clinical
- •evident spinal cord compression.
- •2.Patient known to have a malignancy other than prostate cancer (but not including basal
- •cell carcinoma of the skin).
- •Related to previous or concomitant therapies:
- •3.Previous chemotherapy (including Estramustine) within 6 weeks prior to screening.
- •4.Any other medicine taken with the intension to treat the disease (except LH-RH
- •5.Use of Interferon-alpha, Allopurinol, Sorivudine and analogues and Folinic acid.
- •6.Prior treatment with a systemic radiotherapeutic bone agent (only Sm-153-HEDP,
- •Re-186 HEDP or Re-188-HEDP) within 3 months. Prior treatment with other
- •radiotherapeutic bone agents (e.g., Sr-89-chloride, P-32 -phosphate) within 6 months.
- •7.Patients receiving bisphosphonate therapy must be discontinued for at least 2 weeks
- •prior to treatment with Re-188-HEDP.
- •8.Receipt of any other investigational drug within 4 weeks of study entry.
- •9.Previous hemi-body external radiation therapy.
- •10.Receipt of external beam radiation for bone metastases with irradiation of bone
- •marrow more than 25%, within 6 months of study entry.
- •Related to the patient:
- •11.Known hypersensitivity to 5-FU, Re-188-HEDP, Capecitabine or any of the
- •excipients, or phosphate compounds.
- •12.Patients whose medical history includes clinically significant bleeding disorders which
- •might be exacerbated by study medication.
- •13.Known deficiency of dihydropyrimidine dehydrogenase (DPD).
- •14.Patients with concurrent illnesses or treatments that might preclude study completion
- •or interfere with study results.
- •15.Patients with active CNS (grade 2 or higher) or epidural brain metastasis.
- •16.Clinical diagnosis of disseminated intravascular coagulation
- •17.Absolute neutrophil count, ANC < 2 109/L.
- •18.Platelet count < 150 109/L.
- •19.Hemoglobin < 6 mmol/L.
- •20.Total PSA < 5 µg/L.
- •21.Serum creatinine clearance < 50 ml/min (Cockroft and Gault).
- •22.Bilirubin > 1.5 x ULN.
- •23.SGOT/AST > 2.5 x ULN or SGPT/ALT 2.5 x ULN.
研究者
相似试验
已完成
不适用
The Prostate CARE Study: Capecitabine (Xeloda??) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and phase II efficacy study.Prostate cancer that has spread to the bone1002747610036958NL-OMON30787Academisch Medisch Centrum33
进行中（未招募）
不适用
The Breast CARE Study: Capecitabine (Xeloda®) combined with RHenium-188-HEDP in breast cancer patients with bone metastses; a Re-188-HEDP phase I dose escalation study and phase II efficacy study. - The Breast CARE StudyBreast cancer with painful bone metastases.MedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-004008-38-NLniversity Medical Center Utrecht40
已完成
不适用
The Breast CARE Study: Capecitabine (Xeloda) combined with Rhenium-188-HEDP in breast cancer patients with bone metastases; a Re-188-HEDP phase I dose escalation study and phase II efficacy study.breast cancer that has spread to the bone10027476NL-OMON30358Academisch Medisch Centrum33
进行中（未招募）
1 期
Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancerEUCTR2013-001714-15-ATMed. Univ. Wien, Klinik f. Innere Med. I, Onkologie30
进行中（未招募）
不适用
Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer - HERXECNS-metastasizing HER2-overexpressing breast cancerMedDRA version: 9.1Level: PTClassification code 10057654Term: Breast cancer femaleMedDRA version: 9.1Level: PTClassification code 10006202Term: Breast cancer stage IVEUCTR2007-003634-42-DEKlinikum der Universität München, Standort Großhadern